Dr Agarwal's Hea (AGARWALEYE)

FairStock Score: 38/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am looking at Dr Agarwal's Hea as a hospital business with a fast-growing footprint. The latest quarter shows Sales ₹530 Cr and Net Profit ₹44 Cr, roughly an 8.3% net margin. Five-year revenue CAGR of 26.37% is attractive, and the reported Sales Growth of 95.08% and Profit Growth of 444.02% suggest strong momentum, perhaps from a low base or expansion. Piotroski F-Score of 7/9 is a constructive sign that operations and balance sheet are not deteriorating. Still, the price asks a lot. At ₹506.50 and Market Cap ₹16,055 Cr, the P/E is 108.69, P/B is 7.92, and Book Value is ₹63.93. PEG 3.03 tells me growth is already richly paid for. ROCE of 9.99% is only modest; I want a hospital chain's moat to show up as higher returns on capital. Debt/Equity of 0.50 is not alarming, but Free Cash Flow is ₹-390 Cr. That means growth is swallowing cash. No dividend. Promoter Holding of 32.39% is not a dominant stake. FairStock Score 38/100 is mixed. The 52-week range ₹401-568 shows the stock near its high. For a Graham-style margin of safety, this is not a bargain. For Buffett-style quality, I need ROCE to improve and FCF to turn positive. The business may be a Fast Grower, but the valuation leaves little room for error. I would wait for proof.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer